The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance

Dyslipidaemia plays a prominent role in the genesis of atherosclerotic plaque and the increased cardiovascular risk in diabetes. Macrophages readily take up atherogenic lipoproteins, transforming into foam cells and amplifying vascular damage in the presence of endothelial dysfunction. We discuss th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes and its complications 2023-08, Vol.37 (8), p.108517-108517, Article 108517
Main Authors: Banerjee, Yajnavalka, Patti, Angelo M., Giglio, Rosaria V., Ciaccio, Marcello, Vichithran, Suhina, Faisal, Shemima, Stoian, Anca Panta, Rizvi, Ali Abbas, Rizzo, Manfredi
Format: Article
Language:English
Subjects:
Apolipoproteins
Atherosclerosis
Atherosclerosis - complications
Atherosclerosis - prevention & control
Biomarkers
Cardiovascular disease
Clinical Relevance
Clinical significance
Diabetes
Diabetes Mellitus
Dyslipidemias - complications
Dyslipidemias - drug therapy
Humans
Innovative therapies
Lipids
Lipoproteins
Management
Risk Factors
Small dense lipoprotein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dyslipidaemia plays a prominent role in the genesis of atherosclerotic plaque and the increased cardiovascular risk in diabetes. Macrophages readily take up atherogenic lipoproteins, transforming into foam cells and amplifying vascular damage in the presence of endothelial dysfunction. We discuss the importance of distinct lipoprotein subclasses in atherogenic diabetic dyslipidaemia as well as the effects of novel anti-diabetic agents on lipoprotein fractions and ultimately on cardiovascular risk prevention. In patients with diabetes, lipid abnormalities should be aggressively identified and treated in conjunction with therapeutical agents used to prevent cardiovascular disease. The use of drugs that improve diabetic dyslipidaemia plays a prominent role in conferring cardiovascular benefit in individuals with diabetes. •Diabetes context: dyslipidaemia and atherosclerotic plaque significantly raise cardiovascular risk.•Macrophages' uptake of lipoproteins and foam cell transition intensify vascular damage with endothelial dysfunction.•Identifying lipoprotein subclasses in diabetic dyslipidaemia is crucial to prevent cardiovascular risks.•Impact of new anti-diabetic drugs on lipoprotein fractions is key to lowering cardiovascular risk in diabetes.•Drugs improving diabetic dyslipidemia are essential for cardiovascular benefits in diabetes patients.
ISSN:1056-8727
1873-460X
DOI:10.1016/j.jdiacomp.2023.108517